MannKind (MNKD) Q3 2026 Earnings: Watching the +28% Revenue Growth and Furoscix Ramp

Key Takeaways

• MannKind Corporation (MNKD) is scheduled to report third-quarter 2026 results on November 5, 2026, with a management conference call to follow.
• Wall Street consensus projects revenue of roughly $107 million and a net loss of about $0.06 per share for the quarter.
• Revenue is expected to grow roughly 28% year over year but decline sequentially from Q2's $109.4 million as collaboration and manufacturing revenue cools.
• Furoscix (FURO6) remains the central watch item, with management's reaffirmed full-year guidance of $110 million to $120 million hinging on a second-half ramp.
• The early Afrezza pediatric launch has drawn strong prescriber interest, but payer coverage timing remains an open question for revenue conversion.
• A heavier reported loss may largely reflect known items such as a contingent value right (CVR) payout and new intangible amortization rather than operational weakness.

Why This Earnings Report Matters

MannKind has spent 2026 executing on a catalyst-heavy strategy. Pediatric Afrezza secured FDA approval, the Furoscix ReadyFlow auto-injector cleared regulatory review, and the inhaled nintedanib program posted a clean Phase 1b readout. The third-quarter report marks the company's first full look at a business shifting from launch preparation to commercial execution. Investors are watching whether these wins translate into tangible revenue momentum quickly enough to justify a year of deliberately elevated spending. With the stock trading below its 200-day moving average and sentiment turning more constructive, the print will test whether Furoscix's ramp and Afrezza's pediatric uptake can close the gap between optimism and reported numbers. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Earnings Expectations

Analysts expect MannKind to report revenue of approximately $107 million for the third quarter of 2026, up roughly 28% from the $82.1 million recorded a year earlier. On the bottom line, consensus points to a net loss of about $0.06 per share, a sharp swing from the $0.03 profit reported in the prior-year period. The sequential revenue decline from Q2's $109.4 million is not necessarily a warning sign: management has signaled that the second quarter marked the peak for manufacturing revenue, so some cooling in collaboration and services income is already anticipated. The expected loss also reflects known items, including a $45 million CVR (contingent value right) payout with roughly $16 million of associated expense and about $2.2 million per quarter in new intangible amortization. The most important line to scrutinize will be Furoscix, where Q2 sales of $22.2 million provided a credible base for the year's back half. From what I see, this sets up a clear test for the second-half trajectory.

Market Reaction and Investor Sentiment

Heading into the report, the market has offered MannKind little credit for its catalyst sweep. Shares have declined roughly 8% since the last earnings release while the broader S&P 500 was essentially flat, leaving the stock near $3.50 and below its 200-day moving average of about $3.75. Sentiment, however, has turned noticeably more constructive, shifting from mildly bearish to clearly bullish — a gap that suggests investors want to believe the story but are waiting for proof. Key risk factors include the pace of Furoscix's ReadyFlow inventory conversion, the timing of paid pediatric Afrezza coverage, and any further deceleration in royalty revenue, which slowed to 4% growth last quarter. I’m watching this closely as the numbers come in.

Forward Outlook and Key Factors to Monitor

Furoscix is the primary factor to watch. Management reaffirmed, but did not raise, its full-year 2026 guidance of $110 million to $120 million, which implies roughly $75 million in second-half sales after about $38 million in the first half. A third-quarter figure meaningfully above Q2's $22.2 million would validate that ramp, while a flat result would place heavy pressure on the fourth quarter and invite scrutiny of the guidance range.

The conversion from the older on-body infuser to the ReadyFlow auto-injector is central to that trajectory. Smooth inventory transition supports revenue, while disruption could delay the ramp. Investors should also track Afrezza's pediatric rollout, where early enthusiasm has yet to convert cleanly into revenue because more than half of pediatric scripts have flowed through a cash program pending payer coverage.

Finally, keep an eye on royalty revenue from the United Therapeutics partnership and any commentary on the inhaled nintedanib (MNKD-201) program as it advances toward a global Phase 2 trial. Together, these signals will determine whether the heavy investment phase is translating into durable, visible growth.

Exploring Tickeron’s AI Tools in My Research

In preparing for this report, I turned to Tickeron’s AI Screener to quickly filter comparable names and review pattern signals. It helped surface relevant peers and confirmed the setup around earnings-driven moves without replacing my own analysis. The tool fits naturally into how I scan for context ahead of events like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume